Insider · CIK 0001866256
Rebecca Byam
Files at HCWB (HCW Biologics Inc.). First filing May 9, 2025, latest May 27, 2026.
In brief
Rebecca Byam files SEC Form 4 as CFO at HCWB (HCW Biologics Inc.). Since May 9, 2025, Rebecca Byam has reported 2 open-market buys worth $240k and 0 open-market sells worth $0, the latest filed on May 27, 2026.
A track record needs three past buys with six months of prices behind them; Rebecca Byam has 0, so none is measured yet.
The newest scored trade: bought $20k of HCWB on May 22, 2026, filed May 27, 2026, scored 51 (moderate). In the last 12 months: 1 buy worth $20k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
HCWB: HCW Biologics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | HCW Biologics Inc. | $20k 14,235 shares | +33% | +978% from low-65% from high | |
| 55Moderate | HCW Biologics Inc. | $220k 8,462 shares | +24% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | HCWB HCW Biologics Inc. | POpen-market purchase Common Stock | +14,235 | $1.41 | $20k | 57,245 | May 27, 2026 |
| May 22, 2026 | HCWB HCW Biologics Inc. | POpen-market purchase Common Stock Purchase Warrantderivative | +14,235 | $0.00 | $0 | 18,466 | May 27, 2026 |
| May 8, 2025 | HCWB HCW Biologics Inc. | POpen-market purchase Common Stock | +8,462 | $26.00 | $220k | 43,010 | May 9, 2025 |
| May 7, 2025 | HCWB HCW Biologics Inc. | POpen-market purchase Common Stock Purchase Warrantderivative | +4,231 | $0.00 | $0 | 4,231 | May 9, 2025 |
| Feb 20, 2024 | HCWB HCW Biologics Inc. | AGrant or award Common Stock | +760,714 | $1.40 | $1.1M | 1,381,909 | Feb 22, 2024 |
| Oct 19, 2023 | HCWB HCW Biologics Inc. | MOption exercise Common Stock | +47,249 | $0.14 | $6,615 | 621,195 | Oct 23, 2023 |
| Oct 19, 2023 | HCWB HCW Biologics Inc. | MOption exercise Stock Option Grant (Right to Buy)derivative | -47,249 | $0.00 | $0 | 0 | Oct 23, 2023 |
Questions about Rebecca Byam
Answered from the filings on this page, as of the latest one.
Is Rebecca Byam buying or selling?
In the last 12 months Rebecca Byam reported 1 open-market buy worth $20k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $20k of HCWB on May 22, 2026. Grants, option exercises and tax withholding are not counted.
How did Rebecca Byam's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rebecca Byam has 0.
Where does Rebecca Byam file Form 4?
Rebecca Byam has filed Form 4 at HCWB (HCW Biologics Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.